This one is humming along nicely. It's still interim data and a report to market to 'watch this space'.
Good indications that a larger cohort at full recruitment on the higher dose will re-rate this as they come off study at the back end of the year.
Pretty cool this achievement is not arising from a tailored and expensive immunotherapy pairing but apparently some other response driven by Idronoxil-C, that is impacting distal tumours away from the radio-challenged tumour.
Wondering if other programs will be reported on next week... what did you make of this and the upcoming prezzo @RBx ?
This one is humming along nicely. It's still interim data and a...
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 52445 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 46575 | 3 |
View Market Depth
| Last trade - 11.05am 27/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
Day chart unavailable
